Articles tagged "Immunosuppression"

2020 American Transplant Congress
Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: Update on the Take It Trial
E. Yoon¹, S. Hurr¹, L. Curtis¹, D. Ladner², S. Nair³, M. S. Wolf¹
¹Center for Applied Health Research on Aging (CAHRA), Northwestern University Feinberg School of Medicine, Chicago, IL, ²Surgery, Northwestern Medicine, Chicago, IL, ³Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ
*Purpose: In 2017, the TAKE IT trial began its evaluation of a multifaceted, technology-enabled, transplant center-based intervention to monitor medication adherence behaviors among Kidney Transplant…
2020 American Transplant Congress
Lymph Node Stromal Laminin Alpha5 Regulates Antigen Specific T Cell Adaptive Immunity
L. Li¹, M. Shirkey¹, W. Piao¹, Y. Xiong¹, V. Saxena¹, T. Zhang¹, C. Paluskievicz¹, J. Zhao², R. Abdi², J. S. Bromberg¹
¹UMB, Baltimore, MD, ²Harvard University, Boston, MA
*Purpose: Laminin α5 (Lama5) is associated with immunity and regulates T cell entry and responses within the lymph node (LN). We hypothesized that stromal Lama5…
2020 American Transplant Congress
Co-Stimulatory Blockade Immunosuppression Facilitates Lung Allograft Acceptance Through an Increase in Local IL-5 Production by Type 2 Innate Lymphoid Cells
Y. Guo, Z. Mei, A. Hata, B. Mahgoub, D. Li, A. Manafi, A. Banerjee, A. Gelman, D. Kreisel, A. Krupnick
Surgery, University of Virginia, Charlottesville, VA
*Purpose: We have recently demonstrated that co-stimulatory blockade (CSB)-induced mouse lung allograft acceptance depends on a rapid influx of eosinophils that function to downregulate T…
2020 American Transplant Congress
Evaluation of Tacrolimus Dose Requirement in Liver Transplant Recipients from African American Donors Compared to Non-African American Donors
K. Guilbert, I. Plasari, S. Wiehe, F. Gordon
Lahey Hospital and Medical Center, Burlington, MA
*Purpose: The purpose of this study is to evaluate whether a difference in tacrolimus total daily dose (TDD) exists between those receiving a liver transplant…
2020 American Transplant Congress
Short Term Outcomes in Kidney Transplant Patients Receiving De Novo Belatacept with Anti-Thymocyte Globulin Induction
B. Carlson, P. Cabrera, T. Harrison, K. Tejani, A. Centeno
Pharmacy, Jackson Memorial Hospital, Miami, FL
*Purpose: Mainstay immunosuppressive therapy after kidney transplant is a calcineurin inhibitor (CNI) based regimen. Nephrotoxicity is a common adverse effect of CNIs which can lead…
2020 American Transplant Congress
Efficacy & Safety of Once Daily Tacrolimus Compared to Twice Daily Tacrolimus after Liver Transplantation
K. Bzeizi, A. Albenmousa, M. Shawkat, W. Alhamoudi, S. Alabad, R. Troisi, D. Broering
KFSHRC, Riyadh, Saudi Arabia
*Purpose: To compare the efficacy and safety of once daily prolonged release tacrolimus compared to twice daily tacrolimus in liver transplantation patients*Methods: Medline, EMBASE, CENTRAL…
2020 American Transplant Congress
Evaluation of the Mitra Microsampling Device for TTV Measurement in Human Whole Blood of Lung Transplant Recipients
J. Mühlbacher¹, B. Lickefett¹, K. Doberer², B. Reiter³, S. Aberle⁴, G. Bond², P. Jaksch¹
¹Department of Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Medical University of Vienna, Vienna, Austria, ³Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁴Department of Virology, Medical University of Vienna, Vienna, Austria
*Purpose: The apathogenic Torque Teno Virus (TTV) is highly prevalent among solid organ transplant recipients and mirrors the immunocompetence of its host. qPCR based measurement…
2020 American Transplant Congress
Impact of a De Novo Belatacept Based Immunosuppressive Regimen on Kidney Transplant Outcomes
K. Joyal, T. Vanhove, B. Schreiber, M. Cote, S. Shao, N. Elias, H. Gilligan, K. Safa, E. Heher, W. Williams, C. Rogers
Massachusetts General Hospital Transplant Center, Boston, MA
*Purpose: Use of anti-thymocyte globulin (rabbit) (rATG) induction with belatacept/mycophenolate (MPA)/prednisone based immunosuppression (IS) has led to a reduction in rejection compared to that seen…
2020 American Transplant Congress
A Recombinant, Fully Human ATG Polyclonal Antibody Drug Drives Immune Cell Depletion in a Model of Graft-versus-Host Disease
S. M. Keating, A. S. Adler, R. A. Mizrahi, J. Leong, M. A. Asensio, Y. W. Lim, A. R. Niedecken, Y. Chiang, R. Leong, D. S. Johnson
Immunology, GigaGen, South San Francisco, CA
*Purpose: Anti-thymocyte globulin (ATGs) are polyclonal antibody products that target and deplete T cells for immunosuppression in transplantation (prophylaxis of rejection). Since ATGs are derived…
2020 American Transplant Congress
Belatacept in Kidney Transplant Recipients with Previous Non-Renal Solid Organ Transplants
O. Cristea, C. Larsen, I. Badell
Emory Transplant Center, Emory University School of Medicine, Atlanta, GA
*Purpose: Selective co-stimulatory blockade with belatacept has demonstrated long-term benefits in renal transplantation, with improved glomerular filtration rate and decreased risk of death and graft…